Voronoi Co. Ltd.
Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid ar… Read more
Market Cap & Net Worth: Voronoi Co. Ltd. (310210)
Voronoi Co. Ltd. (KQ:310210) has a market capitalization of $4.17 Billion (₩6.10 Trillion) as of March 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #4481 globally and #84 in its home market, demonstrating a 5.94% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Voronoi Co. Ltd.'s stock price ₩339000.00 by its total outstanding shares 17989720 (17.99 Million).
Voronoi Co. Ltd. Market Cap History: 2022 to 2026
Voronoi Co. Ltd.'s market capitalization history from 2022 to 2026. Data shows growth from $344.31 Million to $4.17 Billion (103.02% CAGR).
Index Memberships
Voronoi Co. Ltd. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$167.61 Billion | 1.43% | #9 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$167.61 Billion | 1.43% | #9 of 1384 |
Weight: Voronoi Co. Ltd.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Voronoi Co. Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Voronoi Co. Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.04x
Voronoi Co. Ltd.'s market cap is 0.04 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $344.31 Million | $9.77 Billion | -$19.90 Billion | 0.04x | N/A |
Competitor Companies of 310210 by Market Capitalization
Companies near Voronoi Co. Ltd. in the global market cap rankings as of March 19, 2026.
Key companies related to Voronoi Co. Ltd. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Voronoi Co. Ltd. Historical Marketcap From 2022 to 2026
Between 2022 and today, Voronoi Co. Ltd.'s market cap moved from $344.31 Million to $ 4.17 Billion, with a yearly change of 103.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩4.17 Billion | +55.86% |
| 2025 | ₩2.67 Billion | +171.88% |
| 2024 | ₩982.91 Million | +48.15% |
| 2023 | ₩663.46 Million | +92.69% |
| 2022 | ₩344.31 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Voronoi Co. Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.17 Billion USD |
| MoneyControl | $4.17 Billion USD |
| MarketWatch | $4.17 Billion USD |
| marketcap.company | $4.17 Billion USD |
| Reuters | $4.17 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.